Bill > HR4752

This bill aims to expand Medicare coverage for individuals with a high risk of hereditary cancer by introducing three key provisions. First, the bill allows Medicare to cover germline mutation testing (genetic testing that identifies inherited genetic changes) for individuals with a personal or family history of hereditary cancer gene mutations, following guidelines from recognized oncology professional organizations. Second, the bill enables Medicare to cover risk-reducing surgeries for individuals where evidence-based clinical guidelines suggest such procedures would lower cancer development risk. Third, the bill mandates increased screening frequency for individuals with identified hereditary cancer gene mutations, including screenings like mammography, breast MRI, colonoscopy, and PSA testing, ensuring these screenings are conducted at least annually and aligned with professional medical guidelines. These changes are designed to help individuals with genetic predispositions to cancer receive proactive medical testing and interventions that could potentially prevent or detect cancer earlier, thereby improving health outcomes and potentially reducing long-term healthcare costs. The amendments will apply to medical services and testing provided on or after the date of the bill's enactment.

Business and Industry

https://www.congress.gov/bill/119th-congress/house-bill/4752/all-info